Neoplastic Syndrome Terminated Phase 2 / 3 Trials for Bevacizumab (DB00112)

Also known as: Neoplastic disease (disorder)

IndicationStatusPhase
DBCOND0028594 (Neoplastic Syndrome)Terminated2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00227617Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsTreatment